anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: An external use skin composition containing a mangrove callus extract is provided to promote collagen synthesis, to suppress inflammation, to remove free radical, and to ensure an excellent anti-aging effect. CONSTITUTION: An external use skin composition for anti-aging contains a mangrove extract. A composition for promoting hair growth or preventing hair loss contains the mangrove extract. An external use skin composition with an anti-oxidation function contains the mangrove extract. An external use skin composition for suppressing inflammation contains a mangrove extract. The mangrove extract is prepared by drying and pulverizing mangrove leaves, stems, or roots. The mangrove extract is a mangrove callus extract.
FIELD: medicinal industry, microbiology, pharmacy. SUBSTANCE: invention relates to Neisseria meningitidis antigens and their compositions. Invention involves protein of genus Neisseria comprising fragment of amino acid sequence containing at least 7 or 14 amino acids of indicated sequence. This sequence elicits property of epitope, antibody that binds with protein specifically, molecule of nucleic acid encoding this protein, molecule of nucleic acid comprising nucleotide sequence that is complementary to nucleic acid molecule, pharmaceutical and vaccine composition used for treatment and prophylaxis of infection caused by Neisseria microorganisms, diagnostic composition for diagnosis of infection caused by Neisseria microorganisms and immunogenic composition used for treatment and prophylaxis of infections caused by Neisseria microorganisms also. The advantage of invention involves the determination of amino acids sequence that shows antigenic and immunogenic properties. EFFECT: valuable medicinal properties of compositions. 18 cl, 23 dwg
The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
The copolymer, for use in polyfunctional bandages with a healing action, is made by mixing an aq. soln. of polyvinyl alcohol, with content of acetate gps. not greater than 20 mol%, with glutaraldehyde in proportion of 8-40 moles per 1000 moles polyvinyl alcohol. Mixing is at 15-80 deg C under static conditions without stirring, after which a mineral acid is added to give pH 1-3. The prod., in hydrogel form, is crumbed in a non-dehydrating medium giving a suspension from which the hydrogel crumb is sepd., treated in succession with water and a polar solvent, and dried.
This study aimed to compare the 2-year cardio-cerebrovascular adverse outcomes of patients with influenza with and without preexisting cardiovascular disease (preCVD) treated with oral antiviral agents in the outpatient clinic. Oral antiviral agents are routinely prescribed to treat influenza infection with a positive rapid-antigen test in the outpatient clinic; however, influenza-associated cardio-cerebrovascular outcomes have not yet been characterized in patients with preCVD treated with oral antiviral agents. Data between 2006 and 2016 were extracted from the National Health Database of South Korea. A total of 865,522 patients with influenza treated with oral antiviral agents were selected in South Korea and classified as preexisting ischemic heart disease (IHD), heart failure (HF), or atrial fibrillation (AF), and 2-year cardio-cerebrovascular outcomes were analyzed using a Cox proportional hazard regression model. Among the participants, 96,433 had preCVD (11.1%; mean age, 46 years) including IHD (86.4%), HF (23.1%), and AF (12.5%). The incidence of new-onset IHD, AF, HF, and death was similar between patients with influenza with and without preCVD. The incidences of IHD and stroke were 0.489 and 0.047 per 100-person year in the preCVD group, respectively. The incidence of cardiovascular mortality was 0.489 per 100-person year in the preCVD group, and the hazard ratio for cardiovascular mortality in the preCVD group was not significantly different from that in patients without preCVD. Based on the national health data, 2-year cardio-cerebrovascular adverse outcomes were not significantly different between patients with and without preCVD treated with oral antiviral agents.
GPs in the intervention arm have to use the web application for every patient at least twice (i.e., at least once a quarter), and have to use at least four specific questionnaires at least once, i.e. 1a is required, and either 2a or 2b, and either 3a or 3b, and either 4a or 4b or 4c. Results from the questionnaires need to be discussed between GPs and patients. Additionally, at least one medication review is obligatory.
Dietary protein is crucial for optimising physical training adaptations such as muscular strength and mass, which are key aims for athletic populations, including British Army recruits. New recruits fail to meet the recommended protein intake during basic training (BT), with negligible amounts consumed in the evening. This study aimed to assess the influence of a daily bolus of protein prior to sleep on performance adaptations, body composition and recovery in British Army recruits. The study will recruit a mixed cohort of \>120 new recruits from the United Kingdom (UK) British Army who will be randomised into a dietary control (CON), carbohydrate placebo (PLA), moderate (20g) protein (MOD) or high (60g) protein (HIGH) supplementation group. Supplements will be isocaloric and consumed daily on weekday evenings between 2000 and 2100h for 10 weeks during BT, alongside standardised dietary intake and BT activities. Performance tests (mid-thigh pull, medicine ball throw, 2km run time, maximal push-up and maximal vertical jump) and body composition will be assessed at the start and end of BT under standardised conditions. Dietary intake, energy expenditure, salivary hormones, urinary nitrogen balance, perceived muscle soreness, rating of perceived exertion, mood and fatigue will be assessed at the start, middle and end of BT. The underlying aim of this study is to assess whether inclusion of nocturnal protein supplementation will influence performance adaptations, body composition changes or acute recovery in British Army recruits.
Highly purified type B hepatitis antigen (HB Age is produced from fluid blood material by maintaining the pH at 4.4-4.7 while adding 4-4.5% polyethylene glycol (I) to ppte. the antigen; then sepg. the ppte. and adding water to give a material having the same antigen concn. as the original blood material, and adjusting to pH 4.9-5.1 to ppte. proteinaceous material; sepg. the ppte. and adjusting the pH of the fluid to 4.4-4.7 and maintaining this pH while adding 4-4.5% (I); and sepg. the pptd. HB Ag.
AIM: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at increased risk of incident cardiovascular disease. However, the clinical characteristics and prognostic importance of MASLD in patients presenting with acute myocardial infarction (AMI) have yet to be examined.
METHODS: This study compared the characteristics and outcomes of patients with and without MASLD presenting with AMI at a tertiary centre in Singapore. MASLD was defined as hepatic steatosis, with at least one of five metabolic criteria. Hepatic steatosis was determined using the Hepatic Steatosis Index. Propensity score matching was performed to adjust for age and sex. The Kaplan-Meier curve was constructed for long-term all-cause mortality. Cox regression analysis was used to investigate independent predictors of long-term all-cause mortality.
RESULTS: In this study of 4446 patients with AMI, 2223 patients with MASLD were matched with patients without MASLD using propensity scores. The mean follow-up duration was 3.4 ± 2.4 years. The MASLD group had higher rates of obesity, diabetes and chronic kidney disease than their counterparts. Patients with MASLD had early excess all-cause mortality (6.8% vs. 3.6%, p < .001) at 30 days, with unfavourable mortality rates sustained in the long-term (18.3% vs. 14.5%, p = .001) compared with those without MASLD. After adjustment, MASLD remained independently associated with higher long-term all-cause mortality (hazard ratio 1.330, 95% confidence interval 1.106-1.598, p = .002).
CONCLUSION: MASLD embodies a higher burden of metabolic dysfunction and is an independent predictor of long-term mortality in the AMI population. Its early identification may be beneficial for risk stratification and provide therapeutic targets for secondary preventive strategies in AMI.
Recent evidence indicates that the gut microbiota (GM) has a significant impact on the inflammatory bowel disease (IBD) progression. Our aim was to investigate the GM profiles, the Microbial Dysbiosis Index (MDI) and the intestinal microbiota-associated markers in relation to IBD clinical characteristics and disease state. We performed 16S rRNA metataxonomy on both stools and ileal biopsies, metabolic dysbiosis tests on urine and intestinal permeability and mucosal immunity activation tests on the stools of 35 IBD paediatric patients. On the GM profile, we assigned the MDI to each patient. In the statistical analyses, the MDI was correlated with clinical parameters and intestinal microbial-associated markers. In IBD patients with high MDI, Gemellaceae and Enterobacteriaceae were increased in stools, and Fusobacterium, Haemophilus and Veillonella were increased in ileal biopsies. Ruminococcaceae and WAL_1855D were enriched in active disease condition; the last one was also positively correlated to MDI. Furthermore, the MDI results correlated with PUCAI and Matts scores in ulcerative colitis patients (UC). Finally, in our patients, we detected metabolic dysbiosis, intestinal permeability and mucosal immunity activation. In conclusion, the MDI showed a strong association with both severity and activity of IBD and a positive correlation with clinical scores, especially in UC. Thus, this evidence could be a useful tool for the diagnosis and prognosis of IBD.
In this study, the investigators propose to create and pilot-test an asynchronous medication abortion (MA) provision service. The foundation of this service will be a website that provides information combined with a linked screening questionnaire. The questionnaire will be designed to collect the information recommended by current MA guidelines for history-based MA eligibility assessment. If the patient's responses meet specified criteria, the questionnaire will be sent to a study clinician, who will then determine whether a real-time clinical consultation or facility-based tests are needed. If the clinician decides that they are not, treatment will be provided accordingly. The primary goal of the study is to collect preliminary data on feasibility of the approach, abortion outcomes, and participant satisfaction. The investigators will use these data to determine whether to proceed with further development of asynchronous MA provision.
Peptides correspond ing to the N-terminal 9 residues of stromal cell derived factor-1 (SDF-1) have SDF-1 activity. Peptides, corresponding to residues 1-8, 1-9, and a disulfide linked dimer of 1-9, involving Cys-9, induced chemotaxis in T lymphocytes and CEM cells, and bound the SDF-1 receptor, CXC chemokine receptor 4 (CXCR4). The peptides had similar activities to SDF-1, but were less potent. Whereas native SDF-I had half maximal chemoattractant activity at 5 nM, the 19 direr and a 1-9 monomer analog were 100- and 3600-fold less potent, respectively. Receptor desensitization and competition binding experiments indicated that the SDF-1 peptides are specific for CXCR4. As Cys-9 is involved in a disulfide bridge with Cys 34 in native SDF-1, it is possible that the disulfide of the peptide dimer enhances its structural similarity to the native protein. Overall this study shows that the N-terminal region is sufficient to bind and activate CXCR4, which suggests the feasibility of designing small CXCR4 agonists or antagonists.
This study will assess the safety and pharmacokinetics of JNJ-39758979 or placebo (which looks like the drug being studied but has no active ingredients) in healthy volunteers. This study is being conducted in two parts. Part 1 is a randomized (study drug will be assigned by chance), double-blind (neither the physician nor volunteer knows the identity of the assigned drug) study evaluating the safety, tolerability and pharmacokinetics of single doses of JNJ-39758979 and placebo in 36 healthy Japanese male volunteers. Part 2 is a randomized, double-blind study evaluating the safety, tolerability, and pharmacokinetics of multiple doses of JNJ-39758979 and placebo in 24 healthy Japanese males and 24 healthy Caucasian males. For Part 1, the participation period is a maximum of 56 days, including a screening visit, a 7-day in-clinic period and two follow-up visits. For Part 2, the participation period is a maximum of 202 days, including a screening visit, a 17-day in-clinic period and two follow-up visits. For both parts of the study, safety evaluations, which will include ECG (a cardiac function test), vital signs and monitoring of side-effects will be performed. Additionally, blood and urine samples will be collected for evaluation. Part 1: volunteers will receive a single oral (by mouth) dose of JNJ-39758979 (50, 100, 300, or 600mg) or placebo; Part 2: volunteers will receive an oral dose of JNJ-39758979 (300 mg) or placebo once a day for 14 days.
This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
Patients will receive either PBMT or sham-PBMT during admission to the hospital. The oral cavity of the patients will be exposed to LED light using a new intra-oral device on the THOR Control Unit at the intensity of 50mW/m2 for 60 seconds per dose. Additionally, the perioral region will be exposed to LED light using an extra-oral device on the THOR Control Unit at the intensity of 50mW/m2 for 60 seconds per dose.
If you agree to take part in this study, you will receive 3 different amounts of lentils which will contain different amounts of the essential amino acid methionine as well as 3 different amount of lentils complemented with rice. The lentils will be cooked in a stew served on its own or served with the rice. The quality of the protein in the lentils will be compared to the quality of a reference protein (egg protein) by giving you 4 reference diets containing amino acids make up like the amino acids in egg protein. The amount of lentils you receive will be provided in a random order.

Breath samples will be collected after the 4th meal in 15 min intervals for 1 hour. Breath collection will resume again two and a half hours after the 5th meal every 15 minutes until 30 minutes after the last meal. A total of 52 breath samples will be collected during each of the 3rd study day.
Anaemia is one of the most common complications of chronic kidney disease (CKD), having a significant impact on quality of life, and is also associated with a number of adverse clinical outcomes. Its pathogenesis is multifactorial, caused largely by an inadequate production of erythropoietin from the diseased kidneys, with iron deficiency, inflammation, shortened red cell lifespan and enhanced blood loss also being contributory factors. The management of this condition was transformed in the late 1980s by the advent of recombinant human erythropoietin (epoetin), and treatment paradigms have developed over the last three decades, largely focusing on a combination of epoetin or its analogues (erythropoiesis-stimulating agents; ESAs) along with iron supplementation, often administered intravenously due to increased hepcidin levels limiting iron absorption from the gut. Indeed, in patients with early CKD and iron deficiency, iron per se may be sufficient to improve the anaemia, delaying the need for ESA therapy. Other causes of anaemia should be excluded and corrected (if possible) before resorting to treatment with ESAs and iron. More recently, the hypoxia-inducible factor-prolyl hydroxylase inhibitors have entered the therapeutic arena; these are orally active agents that upregulate endogenous erythropoietin production as well as a number of iron-regulatory genes which may also enhance erythropoiesis. The latter drugs are highly efficacious, and may have advantages in inflammatory conditions causing resistance to conventional ESA therapy, but concerns exist regarding their safety, particularly in the longer term. This article reviews the current standards of treatment, as well as recent novel developments in the management of anaemia in CKD.
The invention discloses a kluyveromyces lactis with weight-losing and lipid-lowering functions and application thereof, and belongs to the technical field of microorganisms. The Kluyveromyces lactis JSA18 is preserved in China general microbiological culture Collection center (CGMCC No. 26714) and has a preservation date of 2023, 02 and 27 days. The invention utilizes Kluyveromyces lactis JSA18 and uses it in mice which are maintained on a high fat diet, then obtains liver and serum samples, and detects weight change and total cholesterol TC and triglyceride TG levels to evaluate the influence of yeast on obesity and blood lipid. Experiments show that the kluyveromyces lactis JSA18 is well resistant to internal gastrointestinal tract environmental stress. The result shows that the kluyveromyces lactis JSA18 can effectively reduce the hyperlipidemia and fat accumulation caused by obesity, and provides a new treatment way for losing weight and reducing fat.
This study presents a randomized controlled trial design. They will be selected 40 participants diagnosed with knee OA grades II and III, aged 40 and 65 years and BMI \<30 kg / m2 were randomly divided into two groups: participants underwent training (trained group - TG) and not subjected to training ( untrained group - NTG). The participants trained group will undergo a periodized CT protocol of 14 weeks load progression, 3 times a week, with sessions last 15 minutes in the first weeks and will arrive 35 minutes in final weeks, and added 10 minutes between heating and cooling down. All subjects will conduct pre and post CT variables: IMAT thigh (computed tomography); body composition (Dual-energy X-ray absorptiometry - DXA), inflammatory biomarker concentrations: IL-1β, IL-6, IL-10, TNF-α, leptin and adiponectin and joint degradation biomarkers (uCTX-II and sCOMP), performance tests functional (six-minute walk, 30 seconds chair stand test and stair climb test), muscle strength (maximum voluntary isometric contraction - MVIC), WOMAC and KOOS questionnaires, and catastrophizing pain scale. During the training protocol, uCTX-II variables, sCOMP and MVIC will also be evaluated. To compare the groups will be applied the unpaired t-test. When found significant main effects, the Bonferroni test will be used to identify the statistically significant differences. To compare the collections times (pre, during and post TC) for uCTX-II variables, sCOMP and MVIC will be held repeated measures ANOVA with post hoc Bonferroni, and the WOMAC variables, KOOS, DXA, IMAT, functional testing and inflammatory cytokines (pre and post CT) will be held the paired t test. A significance level of 5% (p ≤ 0.05) will be adopted.
NEW MATERIAL:The compound of formula I [X and Y are H, halogen, lower alkyl or lower alkoxy; n is 0-4; R1 is H, lower alkyl or (substituted) phenyl; R2 is lower alkyl, cycloalkyl, lower alkoxy, (substituted) phenoxy, cyclic amino, etc.; R3 is H, lower alkyl or acyl; R2 and R3 may together form a cyclic amino]. EXAMPLE:2-(3-Morpholinopropyl)amino-6-fluoro-8H-indeno[1.2-d]thiazole. USE:A drug having excellent antiulcer activity, low side effect and high safety and useful for the remedy and prevention of ulcer and prevention of relapse of ulcer. PREPARATION:The compound of formula I can be produced by reacting the compound of formula II with the compound of formula III in an organic solvent such as ethanol at 20-120 deg.C for 1-24hr. The produced compound can be converted to a tautomer of formula I wherein R3 is H by the treatment in an aqueous solution of an acid.
FIELD: organic chemistry, cosmetics. SUBSTANCE: invention relates to novel washing and conditioning compositions comprising in cosmetically acceptable aqueous medium the washing base and at least one amphoteric starch taken among compounds of the formulas: (I)  , (II)  , (III)   and (IV)   where St-O means starch molecule; R are similar or different and mean hydrogen atom or methyl radical; R′ are similar or different and mean hydrogen atom, methyl radical or group COOH; n means whole number 2 or 3; M are similar or different mean hydrogen atom, alkaline or alkaline-earth metal, NH 4 , quaternary ammonium or organic amine; R″ means hydrogen atom or alkyl radical comprising from 1 to 18 carbon atoms. Composition does not comprise fatty acid-base soaps. Invention relates also to method of washing and conditioning keratin material, for example, hair. Proposed compositions show excellent cosmetic properties, namely, combing facility, facility and flexibility of treated hair, high specific washing and foam-forming capacity. EFFECT: improved properties of compositions. 22 cl
AIMS: Plasma volume status (PVS), a measure of plasma volume, has been evaluated as a prognostic marker for chronic heart failure. Although the prognostic value of PVS has been reported, its significance in patients with acute decompensated heart failure (ADHF) admitted to the cardiovascular intensive care unit (CICU) remains unclear. In this study, we examined the relationship between PVS and long-term mortality in patients with ADHF admitted to the CICU.
METHODS: Between January 2018 and December 2020, 363 consecutive patients with ADHF were admitted to the Nippon Medical School Hospital CICU. Of the 363 patients, 206 (mean age, 74.9 ± 12.9 years; men, 64.6%) were enrolled in this study. Patients who received red blood cell transfusions, underwent dialysis, were discharged from the CICU or died in the hospital were excluded from the study. We measured the PVS of the patients at admission, transfer to the general ward (GW) and discharge using the Kaplan-Hakim formula. The patients were assigned to four groups according to the quartiles of their PVS measured at each of the three abovementioned timepoints. We examined the association between PVS and all-cause mortality during the observation period (1134 days). The primary endpoint of this study was all-cause mortality.
RESULTS: The Kaplan-Meier analysis showed that the high PVS group had a significantly higher mortality rate at admission, transfer to the GW and discharge than the other groups (log-rank test: P = 0.016, P = 0.005 and P < 0.001, respectively). Univariate Cox regression analysis showed that age, body mass index, history of heart failure, use of beta-blockers, albumin level, blood urea nitrogen level, N-terminal pro-brain natriuretic peptide level and left ventricular ejection fraction were significantly different among the PVS groups and thus were not significant prognostic factors for ADHF. Furthermore, the multivariate analysis revealed that PVS at discharge [hazard ratio (HR) = 1.06 (1.00-1.12), P = 0.048] was an independent poor prognostic factor for ADHF.
CONCLUSIONS: This study highlights the effect of PVS measured at different timepoints on the prognoses of ADHF patients. Regular assessment of PVS, particularly at discharge, is crucial for optimising patient management and achieving favourable outcomes in cases of ADHF.